Premium Essay

Drug Companies

In: Business and Management

Submitted By atrip
Words 1750
Pages 7
WESTERN DRUG COMPANIES AND THE AIDS EPIDEMIC IN SOUTH AFRICA | | | | | | | |

INTRODUCTION
The AIDS epidemic in South Africa is at an extreme where 4.2 million of the country’s 43 million citizens are afflicted. This translates into one in every ten citizens being infected with the virus. Additionally 34 million Sub Saharan African citizens have been afflicted and 11.5 million have died and that total accounts for 83% of the world’s AIDS related deaths.
Treatment is available in the form of an anti-retroviral, but it is very costly and as such unaffordable for the already impoverished nations in Africa. The AIDS crisis and the expensive treatment have caused the government of South Africa to pass laws authorising the practice of parallel importing and compulsory licensing. Parallel importing allows importers to purchase the medication from the cheapest source whether or not the patent holders gave approval and compulsory licensing allows the government to license local companies to produce cheaper versions of the drug patented by foreign companies with or without their consent.
The passing of the law by the South African government caused a legal dispute with the US drug companies regarding intellectual property rights, compulsory licensing and parallel importing. The dispute caused a debate among public health officials, activists, law makers and the drug companies over the importance of public health versus corporate profits and the bad public relations caused the drug companies to drop the law suit added to which they lowered the price of the medication for the African countries and the government was allowed to engage in parallel importing and compulsory licensing..

QUESTION #1
A patent is a property right granted by the Government to an inventor “to exclude others from making, using, offering for sale, or selling the invention…...

Similar Documents

Free Essay

Pharmaceutical Drugs and Drug Companies

...depends on how you look at it, some people conceder drug companies to be monopolistically competitive but I think it is an oligopoly. Oligopoly is a market structure with significant barriers of entry and exit, many consumers and few firms. With a close look of the drug business you will realize that is it has all the characteristics of an oligopoly started above. Because of the fewer number of firms there is always the tendency of collision, secondly in a relatively un-concentrated market barriers to entry and may simply reflect high operating cost. The high cost of getting this product to the market include clinical trials, patent approval and FDA approval; industry-financed studies claimed $114 million 1987, later went up to $231 million, $403 million, and then $2.1 billion in 2006 for FDA approval, patent approval and clinical trials. Oligopolies in most cases tend to go multinational which is largely associated with todays’ drug companies. In terms of research and development, I will say it is the backbone of the pharmaceutical industry which makes it very important. I will want to focus on Pfizer one of the big names in this industry. Pfizer’s Global Research and Development is probably the group that the company takes the most pride in for obvious reasons. If ......

Words: 536 - Pages: 3

Free Essay

Drug Companies

...Answer: Pharmaceutical companies have ethical responsibilities that are to improve the human health and prolonged life that other corporations don’t have. In drug companies ethical values should take priority over economic efficiency. Yes, large US drug companies are good corporate citizens. Some big companies makes drug available at low cost or no cost at all to people with HIV/AIDS in poorer countries. They also donate millions of dollars to nonprofit organization that support patients with life threatening illnesses. Answer: Drug companies don’t have any obligation to make new drug available to patients, who were involved in the development. Yes size of the company does make difference. Big companies can afford to setup their office and absorb the cost of marketing strategy to make the drug available in other developing countries but smaller companies can’t do it. If I were Dr. Lange, I would at least make the drug available to those who were involved in the study. Because it would be violation of ethical obligation and exploitation of human being if they don’t provide the drugs to those patients. The consequences of that the company will be criticized and held morally irresponsible by other patients who won’t be able to get the drug. Answer: Pharmaceutical companies have moral obligation and social responsibility to make the life saving drugs available in poor countries at little or no cost. Disease and illness affect poorest the most and they die of......

Words: 327 - Pages: 2

Free Essay

Western Drug Companies

...Question One: Why is it so important for the drug companies to protect their patents? Answer: In the field of medicine, people begin to focus on intellectual property. Health care related Intellectual Property Right (IPR) is deemed as a special and complex issue, which distinguishes itself from other kinds of IPR with its particular nature and different legal provisions and covers a wide range of subjects. Firstly, medicine is a special and important field of technology. The feature of drug development is large investment, high rise and long cycle. Currently, developing a new chemical drug takes 8 to 10 billion. Moreover, it takes more than ten years to screen a drug and bring it to market. If they don’t protect their patents, new drugs that consumed significant cost will be imitation. Therefore, drug development needs more dependent on protecting patents than other sectors. Secondly, the sustainable development of pharmaceutical industry relies on strong support of new technologies and new products. The return of new drugs is huge and it is over 30 percent of sales. So the huge return needs to be protected. Otherwise it will create duplication of research and development and waste of resources. It is easy to form a vicious marketing competition and goes against technological advances in pharmaceutical industry. For example, an anti-HIV drug successes to be researched and developed in Taiwan. It is said that the effect of prevention of AIDS is 90 percent and an......

Words: 271 - Pages: 2

Premium Essay

Pharmaceutical Companies and the Availability of Hiv Drugs to African Countries

...sold at lower prices abroad (say, in Canada)? Pharmaceutical companies try to maintain a monopoly in the early stages of a drug in order to recover R&D investment. During this period of exclusivity they will try to make a fair profit. This is not a monopoly in the true sense of the word because this period is limited in time. It is perhaps better to describe it as a limited warranty. There are also other limitations. Pharmaceutical companies in some countries may not respect intellectual property and may copy or produce generic drugs even before the patent expires. An important criterion of a monopoly is price control. However, in many countries, a governmental agency is responsible for setting the prices of drugs, making the influence of the manufacturers somewhat limited. This puts pressure on the manufacturers to seek overseas markets in order to maximize their chances of recovering R&D costs and to earn a profit within the period covered by the patent. By so doing the market for re-importation and parallel imports is opened. Some of the prices that the pharmaceutical manufacturers end up accepting under these circumstances do not define a true monopoly. There are several barriers to entry that prevents re-importation into the US of drugs sold at lower prices. These include the following: Price difference Regulatory considerations Trade tariffs Cost of transport Reimbursement procedures Drugs would need to be kept under the same regulatory......

Words: 858 - Pages: 4

Premium Essay

Merck & Company -Evaluating a Drug Licensing Opportunity .Doc

...INTRODUCTION Merck & Company : Evaluating the Licensing Opportunity Various recently-born biotech companies sell their technologies in either finished or early stage to bigger companies in need of financing capital to preceed business, while those bigger companies acquire technologies to scout for promising profitable business. This sort of process needs numbers of decision makings and agreements from both parties on the valuation methods is crucial here. The valuation method being used has to hold objective validity and generality. For the managers to make accurate forecast of future profitability in managing companies, quantified decision making process is needed. Here we are dealing about whether Merck should give financial support to the R&D project of Davanrik offered by LAB, and about the process of valuation and the final decision. First we are to make brief of LAB’s business proposal and practice detailed valuation functions to decide if the proposal is profitable or not. And finally we will make a decision based on the valuation process in perspective of Rich Kender, Vice President of Financial Evaluation & Analysis of Merck. Brief introduction of Merck and its agenda regarding Davanrik project As a world-class pharmaceutical company concentrated on R&Ds, Merck is performing various researches and developments upon medical supplies for human and animals. Merck is providing Pharmaceutical Benefit Management (i.e. PBM) through a company called Merck-Medco......

Words: 1134 - Pages: 5

Premium Essay

Merck & Company - an Opportunity to Evaluate the Licensing of a Drug

...Problem Definition Should Rich Kender recommend licensing Davanrik, making Merck & Company responsible for its manufacture and its marketing? In order to provide Rich Kender with a good and thorough analysis and recommendation on the Davanrik licensing project, we need to answer the following guidance questions: I. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? II. How much should they pay? III. What is the expected value of the licensing arrangement to LAB? IV. How would our analysis change if the costs of launching Davanrik for weight loss were $225 million instead of $100 million? In our analysis we will build a decision tree that shows the cash flows and probabilities at all stages of the FDA approval process. We will assume a royalty fee of 5% on the cash flows that Merck receives from Davanrik after successful launch. Analysis Merck is in the business of developing compounds for pharmaceutical compounds. The required research and development efforts preceding the launch of a successful blockbuster drug is extensive and lengthy process and is therefore a very expensive one. Nevertheless, Merck has proven perfectly capable to achieve high returns on capital. This is a result of numerous factors. First of all, Merck has been able to generate tremendous amounts of sales. Since 1995, Merck has launched 15 new products, resulting in 1999 sales of $32.7 billion,......

Words: 320 - Pages: 2

Premium Essay

Merck & Company: Evaluating a Drug Licensing Opportunity

...Problem Definition Should Rich Kender recommend licensing Davanrik, making Merck & Company responsible for its manufacture and its marketing? In order to provide Rich Kender with a good and thorough analysis and recommendation on the Davanrik licensing project, we need to answer the following guidance questions: I. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? II. How much should they pay? III. What is the expected value of the licensing arrangement to LAB? IV. How would our analysis change if the costs of launching Davanrik for weight loss were $225 million instead of $100 million? In our analysis we will build a decision tree that shows the cash flows and probabilities at all stages of the FDA approval process. We will assume a royalty fee of 5% on the cash flows that Merck receives from Davanrik after successful launch. Analysis Merck is in the business of developing compounds for pharmaceutical compounds. The required research and development efforts preceding the launch of a successful blockbuster drug is extensive and lengthy process and is therefore a very expensive one. Nevertheless, Merck has proven perfectly capable to achieve high returns on capital. This is a result of numerous factors. First of all, Merck has been able to generate tremendous amounts of sales. Since 1995, Merck has launched 15 new products, resulting in 1999 sales of $32.7 billion, which includes $15.2......

Words: 581 - Pages: 3

Premium Essay

Anti-Cancer Drug Cost Regulations- Cocontainment for the Pharmaceutical Companies

...Anti-Cancer Drug Cost Regulations- Cost-Containment for the Pharmaceutical Companies Brenda Roberson University of Maryland University College Abstract Drug development is a long, inefficient, and expensive process and takes 10 to 15 years for development at a cost of about $1.3 billion (Nelson, 2014). When speaking of research and development (R&D) for new drugs; a large number of drugs that go through research do not make it to the FDA or the marketplace. Critics of pharmaceutical companies point out that only a small portion of the pharmaceutical companies’ expenditures account for research and development (R&D). The majority of the money’s spent in marketing and administration. There is also controversy over the $1.3 billion figure as an actual cost. Reported by Nelson (2014) Dr. Kantarjian of M.D. Anderson disputes the $1.3 billion figure for development; he believes this figure to be inflated to cover ancillary expenses, salaries, bonuses, stock market returns, and other indirect costs not related to R&D. The cost of cancer drug therapy is becoming impossible to justify or rationalize for both patient and society. New cancer drugs being approved by the Food and Drug Administration (FDA) are typically costing upwards of $100,000 per year and many times used in combination with other agents (Bunnell, 2012, p. 932) increasing the cost even more. These high priced anti-cancer drugs achieve only marginal benefit for the patient. Benefits achievements of...

Words: 2794 - Pages: 12

Free Essay

Could Changing the Way Drug Companies Create Profits Raise Global Average Life Expectancy?

...Could Changing the Way Drug Companies Create Profits Raise Global Average Life Expectancy? Do you believe the “Fixed Reward Pool” model could help raise global life expectancy? Explain how you came to this decision giving at least 4 pieces of supporting evidence. I do believe that the “Fixed Reward Pool” could potentially raise global life expectancy greatly. The program focuses on rewarding pharmaceutical innovators for their activities. This means pharmaceutical innovators will be driven to help more people, because it will correspond with the amount of profit they will gain. Firstly, the program has a fixed budget. It is a $6 billion plan to decrease unequal distribution of medicine globally, focus more money towards research on diseases with the highest global burden, as well as deliver more medicines cheaply to the poor and develop new medicines for the diseases of the poor. This portends that areas of low income will be more focused on (such as Africa). Areas like Africa with low income are usually areas with low life expectancy, which means these areas will be treated. The people in these areas will get good medical care and medicines, and with a life expectancy rise in this one area, the global life expectancy can potentially have a big rise. The current diseases more looked upon currently, are the less dangerous, more common diseases. In less developed countries, about 50,000 people die daily from diseases caused by poverty (diarrhea, tuberculosis, malaria,......

Words: 667 - Pages: 3

Premium Essay

Merck & Company Evaluating a Drug Licensing Opportunity

...Table of Content | |Page | |1. Executive Summary…………………………………………………………… |1 | |2. Main Report…………………………………………………………………….. |2 | |3. Bibliography…………………………………………………………………….. |6 | 1. Executive Summary In 2002 the patents for the most popular drugs which generated $5.7 billion in worldwide sales would be expired. In order to anticipate the loss of sales, it is recommended to update the product portfolio by investing in the development of patented new products. LAB proposed 17 years exclusivity on Davanrik, a substance which has probability to be efficacious for depression or weight loss or both indications. Up to now LAB has completed preclinical testing and entering clinical testing. The clinical testing will take about 7 years which is divided into 3 phases. Based on the analysis given on the report, the cost on Phase I will come up to $30 million and the Phase II will be $25 million. The outcome of Phase III varies and depends on the result on Phase II. The expected outcomes are: Davanrik is 10% effective for depression only, 15% for weight loss only and 5% for both......

Words: 1007 - Pages: 5

Premium Essay

Psy/425

...Drug-Free Workplace Evaluation Andrew Rhea, Rebecca Chiavetta, Jami Krebs, and Lisa Meier PSY 425 November 12, 2012 Dr. Elizabeth Riegner Drug-Free Workplace Evaluation Imagine an employee is returning from a lunch break, and a coworker is collaborating with this individual in an erratic manner. The coworker’s actions make this employee feel unsafe, and cause him or her to become unproductive. The coworker has an accident, and the company is shutdown to investigate the accident. The previous scenario has often occurred throughout the United States, causing companies to lose money from possible lawsuits, and decreased productivity in the workplace. Illicit, and prescription drug use is prevalent in the United States, and causes absenteeism, accidents, downtime, turnover, theft, morale issues, and decreased productivity in the workplace (University of Phoenix, 2012). This proves that companies benefit from instituting drug-free workplace policies with mandatory drug testing within the workplace. Creating a drug-free work environment is a cost-effective necessity in the workplace, and establishing a drug-free work environment will have positive effects on a company. Prevalence of illicit and prescription drug users in the United States workforce Prescription drugs are "dispensed to the public only with an order given by a properly authorized person" (The Free Dictionary, 2012, p. 1). In 1999, American's spent nearly $104.7 billion on prescription drugs, which......

Words: 1401 - Pages: 6

Premium Essay

Western Drug

...Western Drug Companies and the AIDS Epidemic in South Africa In December 1997, the government of South Africa passed a law that authorized two controversial practices. One, called parallel importing, allowed importers in South Africa to purchase drugs from the cheapest source available, regardless of whether the patent holders had given their approval or not. Thus South Africa asserted its right to import “generic versions” of drugs that are still patent protected. The government did this because it claimed to be unable to afford the high cost of medicines that were patent protected. The other practice, called compulsory licensing, permitted the South African government to license local companies to produce cheaper versions of drugs whose patents are held by foreign companies, irrespective of whether the patent holder agreed. The law seemed to be in violation of international agreements to protect property rights, including a World Trade Organization agreement on patents to which South Africa is a signatory. South Africa, however, insisted that the law was necessary given its own health crisis and the high cost of patented medicines. By 1997, South Africa was wrestling with an AIDS crisis of enormous proportions. It was estimated that over 3 million of the country's 45 million people were infected with the virus at the time, more than in any other country. However, although the AIDS epidemic in South Africa was seen as primary reason for the new law, the law itself was......

Words: 1709 - Pages: 7

Premium Essay

Case Study

...analysis paper, I shall argue that it is morally acceptable for Indian drug companies to copy and sell the AIDS drugs developed by GlaxoSmithKline and Bristol-Myers Squibb. The reasons and evidence that support this moral judgment are as follows: Utilitarianism states that an action is morally correct if the sum total benefits produced by the action is greater than the sum total of benefits produced by any other action that could have been performed in its place. In other words, does the action maximize benefits and minimize injuries to those affected by it? In this case study it’s known that AIDS is a major global problem, and by the Indian drug companies selling the drug developed by GlaxoSmithKline and Bristol-Myers Squibb would help the 28 million people infected with the disease in sub-Saharan Africa where the epidemic is at its worst and most of the individuals affected by it cannot afford the GlaxoSmithKline and Bristol-Myers Squibb made drugs. Since GlaxoSmithKline and Bristol-Myers Squibb will not provide a reasonably priced drug cocktail and the Indian drug companies will, the Indian drug companies will be able to save tens of thousands to hundreds of thousands (possibly even millions) of lives. Preserving life is the ultimate benefit that any action can produce. By preserving life many benefits subsequently follow. The individuals who will now live longer due to the availability of an affordable drug cocktail for their disease will gain the pleasure of......

Words: 2991 - Pages: 12

Premium Essay

Research

...Western Drug Companies and the AIDS Epidemic in South Africa In December 1997, the government of South Africa passed a law that authorized two controversial practices. One, called parallel importing, allowed importers in South Africa to purchase drugs from the cheapest source available, regardless of whether the patent holders had given their approval or not. Thus South Africa asserted its right to import “generic versions” of drugs that are still patent protected. The government did this because it claimed to be unable to afford the high cost of medicines that were patent protected. The other practice, called compulsory licensing, permitted the South African government to license local companies to produce cheaper versions of drugs whose patents are held by foreign companies, irrespective of whether the patent holder agreed. The law seemed to be in violation of international agreements to protect property rights, including a World Trade Organization agreement on patents to which South Africa is a signatory. South Africa, however, insisted that the law was necessary given its own health crisis and the high cost of patented medicines. By 1997, South Africa was wrestling with an AIDS crisis of enormous proportions. It was estimated that over 3 million of the country's 45 million people were infected with the virus at the time, more than in any other country. However, although the AIDS epidemic in South Africa was seen as primary reason for the new law, the law itself was......

Words: 1709 - Pages: 7

Premium Essay

Eli Lily & Co

...Eli Lily & Co History, Development, and Growth of the Company Eli Lilly & Company was founded in 1876 by Colonel Eli Lilly. During the 1880’s Lilly was one of the first companies to invest in Pharmaceutical research by hiring an actual pharmaceutical chemist. In the 1920’s Lilly collaborated on a research effort to purify and isolate insulin for the treatment of diabetes, a fatal disease at that time. This effort resulted in the world’s first commercially available insulin product in 1923. In the 1940’s Lilly was among the first companies to develop a method for mass production of penicillin. In the 1950’s Lilly began to expand in to the world market and began to experiment with different business portfolio strategies. Lilly also launched two powerful antibiotics during this year for patients that did not benefit from or were allergic to penicillin. In 1960 Lilly launched the first in a line oral and injectable antibiotics in the cephalosporin family and two anti cancer drugs. In 1970 Lilly launched the world’s top selling antibiotic, Ceclor. They also began to diversify their portfolio with the purchase of Elizabeth Arden in 1971 and IVAC in 1977. In 1982 Lilly pioneered and introduced the first genetically engineered drug. Lilly also launched a new drug for the treatment of clinical depression in the 1980’s. Prozac became their top seller and accounted for almost 30 percent of the company sales. In the 1990’s Lilly also introduced a stream of innovative......

Words: 3703 - Pages: 15